5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
复制标题
5-S-半胱氨酰多巴诊断黑色素瘤5年经验。
DOI：
10.2340/0001555559381388
复制
发表时间：
1979
影响因子：
3.6
通讯作者：
E. Rosengren
中科院分区：
文献类型：
--
作者：
G. Agrup;P. Agrup;T. Andersson;L. Hafström;C. Hansson;S. Jacobsson;P. Jönsson;H. Rorsman;Rosengren Am;E. Rosengren
对571例黑色素瘤或转移性黑色素瘤患者进行了尿5-S-半胱氨酸多巴测定。在161例有转移的患者中，90%的检测结果超过0.15 mg/24小时，而在410例无转移的患者中，有9%的检测结果为0.15 mg/24小时以上。男性转移者的5-S-半胱氨酸多巴排泄量高于女性，男性98%和女性77%的转移者尿中5-S-半胱氨酸多巴的排泄量超过0.15 mg/24小时，高水平的5-S-半胱氨酸多巴有严重的预后意义，4%的患者在1个月内死亡，仅3%的患者存活超过1年。在瑞典，黑色素瘤手术患者的5-S-半胱氨酸多巴的测定在冬季(10月至3月)提供了最多的信息，此时阳光照射不会影响排泄水平。
Determinations of the urinary excretion of 5-S-cysteinyldopa were performed in 571 patients previously treated by surgery for melanoma or melanoma metastasis. 90% of the 161 patients with metastases showed values exceeding 0.15 mg/24 h, and 9% of the 410 patients without metastases had such values. The increase in 5-S-cysteinyldopa excretion was generally more pronounced in men with metastases than in women, 98% of the men and 77% of the women with metastases showing values exceeding 0.15 mg/24 h. High levels of 5-S-cysteinyldopa are of grave prognostic significan4% died within one month, and only 3% survived for more than a year. In Sweden, determination of 5-S-cysteinyldopa in patients operated on for melanoma gives maximum information in the winter (October--March), when sun exposure does not influence the excretion levels.